CRISPR Therapeutics AG (NASDAQ: CRSP) is -24.52% lower on its value in year-to-date trading and has touched a low of $43.42 and a high of $91.10 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CRSP stock was last observed hovering at around $46.85 in the last trading session, with the day’s gains setting it 0.4%.
Currently trading at $47.25, the stock is -4.18% and -1.32% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.13 million and changing 0.85% at the moment leaves the stock -17.86% off its SMA200. CRSP registered -15.97% loss for a year compared to 6-month loss of -15.96%. The firm has a 50-day simple moving average (SMA 50) of $47.8811 and a 200-day simple moving average (SMA200) of $57.5204.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -2.15% gain in the last 1 month and extending the period to 3 months gives it a -5.18%, and is -8.47% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.20% over the week and 5.00% over the month.
CRISPR Therapeutics AG (CRSP) has around 407 employees, a market worth around $4.07B and $202.83M in sales. Profit margin for the company is -118.13%. Distance from 52-week low is 8.82% and -48.13% from its 52-week high. The company has generated returns on investments over the last 12 months (-11.14%).
with sales reaching $7.7M over the same period.The EPS is expected to shrink by -169.91% this year, but quarterly earnings will post -96.01% year-over-year. Quarterly sales are estimated to shrink -96.17% in year-over-year returns.
CRISPR Therapeutics AG (CRSP) Top Institutional Holders
563.0 institutions hold shares in CRISPR Therapeutics AG (CRSP), with institutional investors hold 73.37% of the company’s shares. The shares outstanding are 85.35M, and float is at 81.64M with Short Float at 22.77%. Institutions hold 72.12% of the Float.
The top institutional shareholder in the company is CAPITAL INTERNATIONAL INVESTORS with over 7.87 million shares valued at $424.8 million. The investor’s holdings represent 9.6159% of the CRSP Shares outstanding. As of 2024-06-30, the second largest holder is ARK INVESTMENT MANAGEMENT LLC with 7.78 million shares valued at $420.12 million to account for 9.5098 of the shares outstanding. The other top investors are SUMITOMO MITSUI TRUST HOLDINGS, INC. which holds 3.15 million shares representing 3.853% and valued at over $170.21 million, while NIKKO ASSET MANAGEMENT AMERICAS, INC. holds 3.853 of the shares totaling 3.15 million with a market value of $169.99 million.
CRISPR Therapeutics AG (CRSP) Insider Activity
The most recent transaction is an insider sale by Kulkarni Samarth, the company’s Chief Executive Officer. SEC filings show that Kulkarni Samarth sold 30,000 shares of the company’s common stock on Nov 11 ’24 at a price of $55.62 per share for a total of $1.67 million. Following the sale, the insider now owns 0.2 million shares.
CRISPR Therapeutics AG disclosed in a document filed with the SEC on Oct 14 ’24 that KASINGER JAMES R. (General Counsel and Secretary) sold a total of 1,089 shares of the company’s common stock. The trade occurred on Oct 14 ’24 and was made at $46.28 per share for $50399.0. Following the transaction, the insider now directly holds 62597.0 shares of the CRSP stock.
Still, SEC filings show that on Oct 14 ’24, Kulkarni Samarth (Chief Executive Officer) disposed off 4,293 shares at an average price of $46.28 for $0.2 million. The insider now directly holds 226,540 shares of CRISPR Therapeutics AG (CRSP).
